Acasti Pharma (ACST) Stock Overview

Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.

ACST Stock Information

Symbol

ACST

Address

3009 boulevard de la Concorde EastLaval, QC H7E 2B5Canada

Founded

Trading hours

Website

https://www.acastipharma.com

Country

🇨🇦 Canada

Phone Number

450-687-2262

Acasti Pharma (ACST) Price Chart

Acasti Pharma Overview: Key Details and Summary

Stock data	2023	Change
Price	$2.29	N/A
Market Cap	$17.03M	N/A
Shares Outstanding	7.44M	21.09%
Employees	0	N/A
Shareholder Equity	67.95M	-37.24%

Valuation	2023	Change
P/E Ratio	-0.40	N/A
P/B Ratio	0.25	N/A

Growth	2023	Change
Return on Equity	-0.6244	N/A

Earnings	2023	Change
Revenue	$0	N/A
Earnings	-$42.43M	N/A
EPS	-5.70	N/A
Earnings Yield	-2.49	N/A

Financial Strength	2023	Change
Total Assets	$79.12M	N/A
Total Debt	$485.00K	N/A
Cash on Hand	$27.89M	N/A
Debt to Equity	0.1643	-12.56%
Cash to Debt	$57.51	-61.15%
Current Ratio	$8.59	-38.18%